Pharmaceutical manufacturer Allergan said Sept. 25 it is releasing a generic version of Janssen's Invega (paliperidone extended release tablets) in the U.S.
Allergan is the first company to receive U.S. Food and Drug Administration approval for a generic version of Invega, which is used to treat schizophrenia in patients aged 12-17.
"This launch reinforces Allergan's commitment to developing, manufacturing and bringing to market high-quality, affordable versions of challenging products like Invega, benefiting patients and reducing health care costs," , Allergan Executive Vice President and President of Generics and Global Operations Robert Stewart said.
Allergan, the third-largest global generics business, markets a portfolio of products for treatment of the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories.
Allergan, based in Dublin, Ireland, is a global, technology-driven multispecialty health care company pursuing therapeutic advances to help patients live life to their fullest potential.
